|Bid||4.50 x 4000|
|Ask||5.31 x 800|
|Day's Range||5.20 - 5.46|
|52 Week Range||4.49 - 7.81|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cerus Corporation announced today that its second quarter 2019 results will be released on Thursday, August 1, 2019, after the close of the stock market. The company will host a conference call and webcast at 4:30 P.M.
Cerus Corporation announced today that multiple abstracts featuring the INTERCEPT Blood System pathogen reduction technology, including four oral presentations, will be included in the scientific program at the 29th regional congress of International Society of Blood Transfusion .
Cerus Corporation (CERS) announced today a new corporate branding campaign building upon the Company’s leadership position in helping to safeguard the world’s blood supply and the planned relocation of its corporate offices to a new facility in Concord California. The new corporate brand reflects Cerus’ increasingly important role in helping blood centers globally to proactively protect the blood supply against the threat of known and emerging infectious diseases. The Company aims to be the global leader in pathogen reduction technologies and a trusted partner of blood centers and hospitals.
Cerus Corporation (CERS) today announced that the FDA has issued a final guidance document recommending protocols for reducing the risk of transfusion transmitted Babesiosis. In 15 Babesiosis endemic states, treating donated blood components with the INTERCEPT Blood System is a recognized alternative to year-round Babesia testing using a DNA-based test. “We are pleased that treating donated blood components with a pathogen-reduction technology such as INTERCEPT was selected as one of the two options recognized by the FDA to reduce the risk of transfusion transmitted Babesiosis,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.
Cerus Corporation (CERS) today announced the closing of a new debt facility with MidCap Financial (MidCap) which is expandable up to $90 million. The debt facility consists of a staged $70 million term loan and a $5 million revolving line of credit, expandable up to $20 million. The new term loan provides an initial tranche of $40 million at closing.
Cerus Corporation (CERS) today announced the appointment of Jami Nachtsheim to its Board of Directors. Ms. Nachtsheim currently serves on the Board at Intuitive Surgical, the global market leader in robotic-assisted minimally invasive surgical systems. Ms. Nachtsheim brings nearly four decades of commercial and marketing leadership experience to the Cerus Board.
Cerus Corporation today announced complete financial results for the fourth quarter and year ended December 31, 2018.
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Cerus Corporation announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market.
Cerus Corporation (CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2018 and provided 2019 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2018 totaled $16.5 million compared to $16.2 million during the same period the prior year. Based on the fourth quarter unaudited preliminary product revenue, the Company expects full year 2018 product revenue to be $60.9 million, ahead of the top end of the range of the Company’s most recent guidance of $58 million to $60 million.
Mr. Moore joins Cerus from Quest Diagnostics, where he served as Vice President, Lab Operations and was previously the Senior Vice President of Operations, Biomedical Services at the American Red Cross, the world’s largest blood center operation.
Cerus Corporation (CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, non-inferiority, Phase 3 study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures. The first patient was enrolled at Houston Methodist Hospital in Houston, Texas. “We are pleased to have started enrollment in ReCePI, our pivotal Phase 3 study,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
Cerus Corporation (CERS) today announced that it has filed for CE Mark registration for the Company’s INTERCEPT red blood cell (RBC) system. “The INTERCEPT RBC CE Mark submission is a major milestone in the Company’s history and represents the culmination of years of effort to complete the full INTERCEPT portfolio of products to help ensure that patients have access to safe blood transfusions,” said William ‘Obi’ Greenman, the Company’s president and chief executive officer. “Red blood cell transfusions are one of the most common hospital procedures globally, and there are more than 25 million red blood cell units transfused in Europe, Middle East and Africa (EMEA) annually.
Cerus Corporation (CERS) announced today that the American Red Cross has received approval by the U.S. Food and Drug Administration (FDA) for their first biologics license application (BLA) for interstate distribution of platelets that have been pathogen-reduced with INTERCEPT Blood Systems. “This BLA approval is a key milestone for Cerus and the American Red Cross,” said Vivek Jayaraman, Cerus’ chief commercial officer.
Cerus Corporation announced today the issuance of a new U.S. Food and Drug Administration draft guidance document on bacterial risk control strategies for platelet collection and transfusion.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Cerus Corporation announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Vivek Jayaraman, Cerus’ chief commercial officer, are scheduled to present a corporate update at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum at 1:30 p.m.
Cerus Corporation announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin Green, Cerus’ vice president, finance and chief financial officer, are scheduled to present a corporate update at the 2018 Stephens NY Investment Conference at 9:45 a.m.
Cerus Corporation (CERS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s pathogen-reduced cryoprecipitate product candidate. The basis of the designation is improved treatment of massive hemorrhage, a life-threatening medical condition. "The proposed label indication for pathogen-reduced cryoprecipitate would be to control massive bleeding associated with fibrinogen deficiency,” said Dr. Laurence Corash, Cerus’ chief scientific officer.
Cerus Corporation announced today that its third quarter results will be released on Thursday, November 1, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 P.M.